This event brings together leading experts to discuss the current landscape, challenges, and innovative developments in the field.
From a detailed overview of lung cancer types and existing treatments to insights into immune-oncology (IO) advancements, small molecules, antibody-drug conjugates (ADCs), and biomarkers, this gathering will be a comprehensive exploration of the complexities in lung cancer care.
Date: 14th of Maj 2024
Time: 14.00 – 18.00
Venue: Malmö University, Niagara, Hörsal B2, Nordenskiöldsgatan 1, Malmö, Sweden
(5 min. walk from Malmö C station)
Program:
| 14.30 | Registration and networking |
| 15:00 | Welcome Katrine Brems Olsen, Head of Networks, Medicon Valley Alliance |
| 15:10 | Overview of current progress in Lung Cancer and future prospects Jens Benn Sørensen, MD, DMSc, Assoc. Professor and Chief Physician, Department of Oncology, Rigshospitalet, Copenhagen University Hospital |
| 15:40 | Immune Modulatory Vaccines to treat solid tumours Ayako Wakatsuki Pedersen, VP Translational Research, IO Biotech |
| 16:00 | The evolution of Antibody-drug conjugates – ADCs Martin Avander, Medical Manager, Daiichi Sankyo |
| 16:20 | Coffee break and networking |
| 16:50 | Small Molecules as Precision Weapons in Lung Cancer Therapy Lars Ringgaard, Disease area specialist oncology portfolio, Nordics, AstraZeneca |
| 17:10 | Biomarkers in lung cancer- current uses, unmet needs and future perspectives Elsa Arbajian, Assistant researcher, LUCC: Lund University Cancer Centre |
| 17:30 | Panel discussion Moderated by Jan Stenvang, CSO and Co-Founder, Scandion Oncology |
| 18:00 | Networking and sandwiches |
| 18:30 | End of meeting |
Speakers
 |
Dr. Jens Benn Sørensen has special interest in Thoracic Oncology and a research focus on Medical Oncology in Lung Cancer and in Malignant Pleural Mesothelioma. He has previously served as Board Member of the International Association for the Study of Lung Cancer (IASLC). He currently serves as Board Member of Danish Lung Cancer Group, Danish Lung Cancer Registry, and is Chairman of the Danish Mesothelioma Group. Dr Sørensen is the author of more than 200 papers published in indexed peer-reviewed international journals and he has been an invited speaker to several national and international oncology meetings. He is also recipient of the European Respiratory Society (ERS) European Award for Achievement in the field of Non-Small cell Lung Cancer (NSCLC). |
 |
Ayako Wakatsuki Pedersen is a biotech professional with a PhD in Immunology, with over 15 years of experience in immune-oncology therapeutics development. Currently she is leading preclinical and translational research at IO Biotech, pioneering the first-in-class immune modulating cancer vaccines. |
 |
Martin Avander works as the medical lead for lung cancer at the Nordic affiliate of Daiichi Sankyo. He is a pharmacist by training and has spent 15 years in the pharmaceutical industry. In his current role he coordinates the clinical and scientific work on Antibody Drug Conjugates (ADCs). |
 |
Lars Ringgaard is a seasoned Medical Affairs Professional with a strong scientific foundation. With a Ph.D. within Drug Delivery and anticancer therapy, which he has applied extensively in the field of translational research, he effortlessly navigate the intersection of science and medicine. He has a dedication to improve patient care that shines through his practical contributions in the development of innovative medical solutions. |
 |
Elsa Arbajian is currently Associate Researcher in the lung cancer research group co-led by Maria Planck and Johan Staaf at the division of oncology, Lund University. The research group focuses on characterisation of lung cancer subgroups using multiple omic methods, in both own and public cohorts. The group aims to find new molecular subgroups of potential clinical relevance, additional treatment targets, as well as prognostic and/or treatment predictive biomarkers. |
|
|
Jan Stenvang is CSO in Scandion Oncology, which he co-founded in 2027. The company is currently testing their lead compound in Phase I and Phase II clinical trials. He is also Associate Professor at the University of Copenhagen with 20 years of post doc/group leader experience and solid knowledge in basic research on resistance model systems in cancer. Throughout his career he has worked in the interface between basic translational cancer research and private biotech companies. He has been employed both in the private and the public sector and have through many project collaborations contributed to improved basic insight into cancer resistance mechanisms, initiation of investigator initiated clinical trials and development of new products for several companies. |
Deadline for registration is 10 May 2024
The MVA Oncology Network
Is a professional and social network for professors, PIs and corporate level executives from the regional oncology eco-system. The network focuses on best practice, experience and current challenges for public-private collaboration and the commercialization of oncology related R&D in the Medicon Valley region.
Joining the network is free of charge and is limited to Medicon Valley Alliance members only. However, non-member organizations and companies are welcome to attend one network event to evaluate if joining the network is relevant. If so, becoming a member of Medicon Valley Alliance will automatically allow you to join the oncology network.
| Organized by | |
 |
|